Evidence map›Paper›PMID 25409514›Full record

ArticlePloS one2014

The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells.

Anuran Chatterjee, Anjali Sharma, Mian Chen, Robert Toy, Giorgio Mottola, Michael S Conte

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02719665 (THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02719665 nacompletednot on this mapstarted 2016, after this paper: background citation

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2020Enrolled30ConditionsPeripheral Arterial Disease, Claudication, Claudication, Intermittent, Vascular OcclusionArmsSPM Emulsion, Dose-modality, SPM Softgel, Dose-Modality, Placebo Softgel
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016
    Trial
  4. Article
  5. Review
  6. Maresins.Biomolecules · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Involvement of Inflammation and Its Resolution in Disease and Therapeutics.International journal of molecular sciences · 2022
    Review
  18. Molecular Pharmacology of Inflammation Resolution in Atherosclerosis.International journal of molecular sciences · 2022
    Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anuran ChatterjeeCardiovascular Research Institute (CVRI) and Department of Surgery, University of California San Francisco, San Francisco, California.
Anjali SharmaCardiovascular Research Institute (CVRI) and Department of Surgery, University of California San Francisco, San Francisco, California.
Mian ChenCardiovascular Research Institute (CVRI) and Department of Surgery, University of California San Francisco, San Francisco, California.
Robert ToyCardiovascular Research Institute (CVRI) and Department of Surgery, University of California San Francisco, San Francisco, California.
Giorgio MottolaCardiovascular Research Institute (CVRI) and Department of Surgery, University of California San Francisco, San Francisco, California.
Michael S ConteCardiovascular Research Institute (CVRI) and Department of Surgery, University of California San Francisco, San Francisco, California.
University of California, San Francisco · US

Funding

Specialized lipid mediators and mechanisms of resolution in vascular injuryR01HL119508 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CONTE, MICHAEL S · 2013 to 2016
$1.5M
NHLBI NIH HHS HL119508NHLBI NIH HHS R01 HL119508
6 · The paper itself

Abstract

objectiveInflammation and its resolution are central to vascular injury and repair. Maresins comprise a new family of bioactive lipid mediators synthesized from docosahexaenoic acid, an ω-3 polyunsaturated fatty acid. They have been found to exert anti-inflammatory and pro-resolving responses in macrophages, neutrophils and bronchial epithelial cells and impart beneficial actions in murine models of peritonitis and colitis. We investigated the impact of maresin-1 (MaR1) on tumor necrosis factor alpha (TNF-α) induced inflammatory responses in human vascular endothelial (EC) and smooth muscle cells (VSMC).

methodsPrimary cultures of human saphenous vein EC and VSMC were employed. We tested the naturally occurring MaR1 as modulator of TNF-α effects, with examination of monocyte adhesion, oxidant stress, and intracellular inflammatory signaling pathways.

resultsMaR1 attenuated TNF-α induced monocyte adhesion and reactive oxygen species (ROS) generation in both EC and VSMC, associated with down-regulated expression (cell surface) of the adhesion molecule E-selectin (in EC) and NADPH-oxidases (NOX4, NOX1, NOX2). MaR1 attenuated TNF-α induced release of pro-inflammatory mediators by EC and VSMC. MaR1 caused an attenuation of TNF-α induced NF-κB activation in both cell types associated with inhibition of I-κ Kinase (IKK) phosphorylation, IκB-α degradation and nuclear translocation of the NF- κB p65 subunit. MaR1 also caused a time-dependent increase in intracellular cyclic AMP (cAMP) in both naive and TNF-α stimulated VSMC and EC.

conclusionsMaR1 has broad anti-inflammatory actions on EC and VSMC, which may be partly mediated through up-regulation of cAMP and down-regulation of the transcription factor NF-κB. The results suggest that the pro-resolving lipid mediator MaR1 exerts homeostatic actions on vascular cells that counteract pro-inflammatory signals. These findings may have direct relevance for acute and chronic states of vascular inflammation.

Indexed as

Cell AdhesionCells, CulturedCyclic AMPDocosahexaenoic AcidsDown-RegulationEndothelial CellsE-SelectinHumansMuscle, Smooth, VascularNADPH OxidasesNF-kappa BOxidative StressPhosphorylationReactive Oxygen SpeciesSignal TransductionTranscription Factor RelA7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidCyclic AMPDocosahexaenoic AcidsE-SelectinNADPH OxidasesNF-kappa BReactive Oxygen SpeciesTranscription Factor RelATumor Necrosis Factor-alpha

Identifiers

PMID25409514
PMCPMC4237455
OpenAlexW2003968006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.